The couvet site is constructed in 2018, designed with industry-leading energy efficiency and environmental standards and has been inspected by US FDA, EMA, Japan PMDA, and SwissMedic multiple times in 2018-2023.
This site offers commercial drug product manufacturing of oral solids with packaging and labeling capabilities. It is current producing a top-5 global selling drug for 8 different markets including the US, UK, Europe, Canada, Japan, Switzerland, Australia and New Zealand.
In the next 2-3 years, the current manufacturing and packaging capacities will be doubled. The site will also add injectable manufacturing lines, lipid nanoparticle, and spray dried dispersion.
